Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Digital IHC Solution, integrated image analysis for Breast Cancer introducted by Aperio Technologies

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Philips Elevate Plus Gains FDA Clearance...

Philips announced that it has obtained FDA clearance for...

Smith+Nephew Launches Next-Generation LEAF Platform for...

Smith+Nephew has announced the launch of its next-generation LEAF...

Multimodal AI Advancing Next Generation Clinical...

Multimodal AI is advancing next-generation clinical workflows by combining data from medical imaging, electronic health records, and genomic profiles into a unified decision-making framework. This enables more accurate diagnoses, personalized treatments, and streamlined clinical operations, improving both healthcare efficiency and patient outcomes.

Aperio Technologies, Inc., a global leader in digital pathology for the healthcare and life sciences industry, is announced the launch of a digital pathology solution for Immunohistochemistry designed specifically for the clinical market.

Aperio’s digital IHC solution is the only commercially available FDA-cleared system allowing pathologists to run quantitative IHC image analysis while reading slides on a computer monitor. 

A digital IHC system significantly streamlines clinical workflow. By using a single system to read digital IHC slides, perform quantitative image analysis, and create professional reports, pathologists can provide faster turn-around times, more informed decision-making, and accurate and consistent test results.

Eric F. Glassy, MD, medical director at Pathology Inc., stated, After switching to Aperio's digital IHC solution from a different computer-assisted technology, we immediately experienced improved efficiency. More importantly, the interpretation algorithms offer far more control and accuracy, and the reporting capability is superior. We especially appreciate the ability to link thumb nail images on the PDF file to the actual whole slide images. The power and flexibility are simply remarkable.

The digital IHC system includes FDA-cleared algorithms for HER2, ER and PR stained breast specimens for diagnosing digital slides for clinical use in pathology. In addition, the system comes with a suite of image analysis algorithms that can be tuned for different tissue types (e.g. breast, colon, prostate), stains (e.g. HER2, ER, PR, Ki-67, P53, EGFR), reagents (e.g. Dako, Ventana) or to correlate algorithm results with other test methods (e.g. FISH, CISH).

Dirk Soenksen, CEO of Aperio said, An integrated system is key to providing an efficient workflow for pathologists, and a major advantage over add-on image analysis systems. Pathologists can now use Aperio’s sophisticated cell-based image analysis capabilities with the click of a button while reading a slide.

Aperio’s versatile digital pathology platform allows laboratories and pathologists to adopt digital pathology in applications like IHC and then expand the utility of the system to many other digital pathology services such as secondary consultations, tumor boards, quality assurance programs, and proficiency testing and training.

About Aperio

Aperio is digitizing pathology. We provide systems and services for digital pathology, which is an environment for the management and interpretation of pathology information that originates with the digitization of a glass slide. Aperio’s award-winning ScanScope® slide scanning systems and Spectrum™ digital pathology information management software improve the efficiency and quality of pathology services for pathologists and other professionals. Applications include education, remote viewing, archival and retrieval, basic research and image analysis. Aperio’s products are FDA cleared for specific clinical applications, and are intended for research and education use for other applications. For clearance updates and more information, please visit www.aperio.com.

Media Inquiries:

Myla Wagner
Myla Wagner Public Relations
925.736.7515
myla@mylawagnerpr.com

Product Inquiries:

Kevin Whiteley
Vice President, Marketing
Aperio
760.539.1177
kwhiteley@aperio.com

Hospital & Healthcare Management brings together the global healthcare industry — from hospital administrators and clinical directors to health technology innovators and policy leaders — through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium healthcare industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global hospital and healthcare management value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.
MEDICAL FAIR ASIA 2026
MEDICAL FAIR CHINA

Latest stories

Related stories

Philips Elevate Plus Gains FDA Clearance for AI Ultrasound

Philips announced that it has obtained FDA clearance for...

Smith+Nephew Launches Next-Generation LEAF Platform for Remote Patient Monitoring

Smith+Nephew has announced the launch of its next-generation LEAF...

Multimodal AI Advancing Next Generation Clinical Workflows

Multimodal AI is advancing next-generation clinical workflows by combining data from medical imaging, electronic health records, and genomic profiles into a unified decision-making framework. This enables more accurate diagnoses, personalized treatments, and streamlined clinical operations, improving both healthcare efficiency and patient outcomes.

Digital Biomarkers Enhancing Continuous Health Assessment

Digital biomarkers are enhancing continuous health assessment by using data from wearables, smartphones, and connected devices to monitor patients in real time. This approach provides deeper insights into health trends, supports earlier interventions, and improves preventive care and chronic disease management beyond traditional clinical visits.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »